Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 3/2007

01-03-2007 | Original Paper

Roles of EGFR-Stat3 signal pathway in carcinogenesis of experimental hepatoma in rats

Authors: Xiao Tang Yu, Shi Neng Zhu, Zu De Xu, Xi Qi Hu, Teng Fang Zhu, Jie Qing Chen, Shi Lun Lu

Published in: Journal of Cancer Research and Clinical Oncology | Issue 3/2007

Login to get access

Abstract

The purpose of this study is to investigate if the EGFR-Stat3 signal pathway contributes to the carcinogenesis of hepatoma in rats. Hepatoma was induced in rats by 3′Me-DAB as a model. EGFR, TGFα, Stat3, p-Stat3 in different stages of carcinogenesis were detected by immunohistochemistry and Western blot. In situ hybridization was applied to investigate the expression of Stat3 mRNA. The expressions of signal molecules were assessed by KS400 Image Analysis system. The data were statistically evaluated. EGFR, TGFα, Stat3 were highly expressed in the stages of liver necrosis and repairment. All hepatocellular carcinoma cases revealed elevated expression of EGFR, TGFα. Elevation of Stat3 mRNA and protein levels were identified, increase of activation of Stat3 was also observed. In HCC, there was positive correlation between p-Stat3 level and the expression of TGFα and PCNA. Increased expression of Bcl-2 (P < 0.05) coincided with elevated level of p-Stat3. Therefore, the EGFR-Stat3 signal pathway was related to the development of hepatoma in rats. TGFα-EGFR autocrine ring formation may lead to the activation of Stat3 and in turn, promote proliferation and regulate the transcription of genes regulating cell apoptosis and cell cycle.
Literature
go back to reference Burr AW, Toole K, Mathew J, Hines JE, Chapman C, Burt AD (1996) Transforming growth factor-alpha expression is altered during experimental hepatocarcinogenesis. J Pathol 179(3):276–282PubMedCrossRef Burr AW, Toole K, Mathew J, Hines JE, Chapman C, Burt AD (1996) Transforming growth factor-alpha expression is altered during experimental hepatocarcinogenesis. J Pathol 179(3):276–282PubMedCrossRef
go back to reference Calo V, Migiliavacca M, Bazan V et al (2003) STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 197(2):157–168PubMedCrossRef Calo V, Migiliavacca M, Bazan V et al (2003) STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 197(2):157–168PubMedCrossRef
go back to reference Chan KS, Carbajal S, Kiguchi K, Clifford J, Sano S, DiGiovanni J (2004) Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis. Cancer Res 64:2282–2389CrossRef Chan KS, Carbajal S, Kiguchi K, Clifford J, Sano S, DiGiovanni J (2004) Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis. Cancer Res 64:2282–2389CrossRef
go back to reference Chung YH, Kim JA, Song BC et al (2000) Expression of transforming growth factor-alpha mRNA in livers of patients with chronic viral hepatitis and hepatocellular carcinoma. Cancer 89:977–982PubMedCrossRef Chung YH, Kim JA, Song BC et al (2000) Expression of transforming growth factor-alpha mRNA in livers of patients with chronic viral hepatitis and hepatocellular carcinoma. Cancer 89:977–982PubMedCrossRef
go back to reference Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL (2003) Tissue microarray analysis of signal transducers and activators of transcription 3(Stat3) and phosphor-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 9:594–600PubMed Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL (2003) Tissue microarray analysis of signal transducers and activators of transcription 3(Stat3) and phosphor-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 9:594–600PubMed
go back to reference Grandis JR, Drenning SD, Chakraborty A et al (1998) Requirement of Stat3 but not Stat1 Activation for Epidermal Growth Factor Receptor–mediated Cell Growth In Vitro. J Clin Invest 102:1385–1392PubMedCrossRef Grandis JR, Drenning SD, Chakraborty A et al (1998) Requirement of Stat3 but not Stat1 Activation for Epidermal Growth Factor Receptor–mediated Cell Growth In Vitro. J Clin Invest 102:1385–1392PubMedCrossRef
go back to reference Jorissen RN, Walker F, Pouliot N, Garrett TPJ, Ward CW, Burgess AW (2003) Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res 284:31–53PubMedCrossRef Jorissen RN, Walker F, Pouliot N, Garrett TPJ, Ward CW, Burgess AW (2003) Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res 284:31–53PubMedCrossRef
go back to reference Kuan CT, Wikstrand CJ, Bigner DD (2001) EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 8(2):83–96PubMedCrossRef Kuan CT, Wikstrand CJ, Bigner DD (2001) EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 8(2):83–96PubMedCrossRef
go back to reference Lee GH, Merlino G, Fausto N (1992) Development of liver tumors in transforming growth factor alpha transgenic mice. Cancer Res 52:5162–5170PubMed Lee GH, Merlino G, Fausto N (1992) Development of liver tumors in transforming growth factor alpha transgenic mice. Cancer Res 52:5162–5170PubMed
go back to reference Liu VW, Grandis JR (2002) EGFR-mediated cell cycle regulation. Anticancer Res 22(1A):1–11 Liu VW, Grandis JR (2002) EGFR-mediated cell cycle regulation. Anticancer Res 22(1A):1–11
go back to reference Masson S, Daveau M, Hiron M et al (1999) Differetial regenerative response and expression of growth factors following Hepatoectomy of variable extent in rats. Liver 19:312–317PubMed Masson S, Daveau M, Hiron M et al (1999) Differetial regenerative response and expression of growth factors following Hepatoectomy of variable extent in rats. Liver 19:312–317PubMed
go back to reference Morimitsu Y, Hsia CC, Kojira M et al (1995) Nodules of less-differentiated tumor within or adjacent to hepatocellular carcinoma: relative expression of transforming growth factor-α and its receptor in the different areas of tumor. Hum Pathol 26(10):1126–1132PubMedCrossRef Morimitsu Y, Hsia CC, Kojira M et al (1995) Nodules of less-differentiated tumor within or adjacent to hepatocellular carcinoma: relative expression of transforming growth factor-α and its receptor in the different areas of tumor. Hum Pathol 26(10):1126–1132PubMedCrossRef
go back to reference Sánchez A, Nagy P, Thorgeirsson SS (2003) STAT-3 activity in chemically-induced hepatocellular carcinoma. Eur J Cancer 39(14):2093–2098PubMedCrossRef Sánchez A, Nagy P, Thorgeirsson SS (2003) STAT-3 activity in chemically-induced hepatocellular carcinoma. Eur J Cancer 39(14):2093–2098PubMedCrossRef
go back to reference Thorgeirsson SS, Grisham JW (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31:339–346PubMedCrossRef Thorgeirsson SS, Grisham JW (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31:339–346PubMedCrossRef
go back to reference Tidow N, Boecker A, Schmidt H et al (2003) Distinct amplification of an untranslated regulatory sequence in the EGFR gene contributes to early steps in breast cancer development. Cancer Res 63(6):1172–1178PubMed Tidow N, Boecker A, Schmidt H et al (2003) Distinct amplification of an untranslated regulatory sequence in the EGFR gene contributes to early steps in breast cancer development. Cancer Res 63(6):1172–1178PubMed
go back to reference Toyoda M, Hashimoto N, Tokita K et al (1999) Increased activity and expression of MAP kinase in HCC model rats induced by 3′-methyl4dimethylamino-azobenzene. J Hepatol 31:125–133CrossRef Toyoda M, Hashimoto N, Tokita K et al (1999) Increased activity and expression of MAP kinase in HCC model rats induced by 3′-methyl4dimethylamino-azobenzene. J Hepatol 31:125–133CrossRef
go back to reference Wang QS, Sabourin CLK, Bijur GN, Robertson FM, Stoner GD (1996) Alterations in transforming growth factor-alpha and epidermal growth factor receptor expression during rat esophageal tumorigenesis. Mol Carcinog 15:144–153PubMedCrossRef Wang QS, Sabourin CLK, Bijur GN, Robertson FM, Stoner GD (1996) Alterations in transforming growth factor-alpha and epidermal growth factor receptor expression during rat esophageal tumorigenesis. Mol Carcinog 15:144–153PubMedCrossRef
go back to reference Yamaguchi K, Carr BI, Nalesnik MA (1995) Concomitant and isolated expression of TGF-alpha and EGF-R in human hepatoma cells supports the hypothesis of autocrine, paracrine, and endocrine growth of human hepatoma. J Surg Oncol 58:240–245PubMed Yamaguchi K, Carr BI, Nalesnik MA (1995) Concomitant and isolated expression of TGF-alpha and EGF-R in human hepatoma cells supports the hypothesis of autocrine, paracrine, and endocrine growth of human hepatoma. J Surg Oncol 58:240–245PubMed
go back to reference Zhong Z, Wen ZL, Darnel JE (1994) Stat3 and stat4: members of the family of signal transducers and activators of transcription. Proc Natl Acad Sci USA 91:4806–4810PubMedCrossRef Zhong Z, Wen ZL, Darnel JE (1994) Stat3 and stat4: members of the family of signal transducers and activators of transcription. Proc Natl Acad Sci USA 91:4806–4810PubMedCrossRef
Metadata
Title
Roles of EGFR-Stat3 signal pathway in carcinogenesis of experimental hepatoma in rats
Authors
Xiao Tang Yu
Shi Neng Zhu
Zu De Xu
Xi Qi Hu
Teng Fang Zhu
Jie Qing Chen
Shi Lun Lu
Publication date
01-03-2007
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 3/2007
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-006-0139-z

Other articles of this Issue 3/2007

Journal of Cancer Research and Clinical Oncology 3/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.